文献速递骨软组织肉瘤与黑色素瘤

帕唑帕尼联合术前放化疗治疗儿童及成人晚期软组织肉瘤的病理缓解:ARST1321随机II期试验

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2020-07-20

ARST1321是一项多中心随机开放标签II期试验,纳入81例不可切除的中高级别躯干或肢体化疗敏感软组织肉瘤儿童及成人患者,比较术前放化疗联合或不联合帕唑帕尼的病理近完全缓解率。帕唑帕尼组3-4级不良事件更常见,生存获益需更长期随访。

要点

  • 帕唑帕尼联合术前放化疗使90%及以上病理缓解率从22%提高至58%。
  • 帕唑帕尼组3-4级血液学毒性更常见,但儿童与成人毒性相似。

核心结论

  • 在不可切除的中高级别软组织肉瘤儿童和成人中,术前放化疗联合帕唑帕尼较单纯放化疗提高了病理近完全缓解率。
  • 该联合方案在儿童和成人中可行且活性高,但生存结局比较需要更长随访。

研究设计与样本

  • 多中心、随机、开放标签、II期试验,由Children's Oncology Group与NRG Oncology联合开展,注册号NCT02180867。
  • 纳入81例不可切除、新诊断的躯干或肢体化疗敏感软组织肉瘤患者,肿瘤直径大于5cm、中或高级别,年龄2岁及以上。
  • 患者随机1:1接受术前异环磷酰胺+多柔比星+45Gy放疗联合或不联合口服帕唑帕尼,第13周手术切除。
  • 研究预设需100例随机患者以检测90%及以上病理缓解率从40%提高至60%,实际入组81例后因中期分析跨过边界而停止。

主要发现

  • 第二次中期分析时42例可评估,帕唑帕尼组24例中14例(58%)达到90%及以上病理缓解,对照组18例中4例(22%)。
  • 帕唑帕尼组最常见的3-4级不良事件为白细胞减少(16/37,43%)、中性粒细胞减少(15/37,41%)和发热性中性粒细胞减少(15/37,41%)。
  • 对照组3-4级中性粒细胞减少和发热性中性粒细胞减少均为3/35(9%)。
  • 帕唑帕尼组37例中22例(59%)发生帕唑帕尼相关严重不良事件;儿童与成人3-4级毒性数量相似;共7例死亡(帕唑帕尼组3例,对照组4例),均与治疗无关。

关键数值与推荐

  • 主要终点为第13周90%及以上病理缓解率,预设从40%提高至60%具有临床意义。
  • 帕唑帕尼剂量:小于18岁患者350mg/m2每日一次;18岁及以上患者600mg每日一次。

临床怎么用

  • 对于不可切除的中高级别躯干或肢体软组织肉瘤儿童及成人,可考虑术前放化疗联合帕唑帕尼以提高病理缓解率。
  • 联合帕唑帕尼时需密切监测血液学毒性,尤其是白细胞减少、中性粒细胞减少和发热性中性粒细胞减少。
  • 帕唑帕尼相关严重不良事件发生率较高,治疗期间需加强不良事件管理。

局限性

  • 研究因中期分析显示疗效优势而提前终止入组,实际样本量81例低于预设的100例。
  • 开放标签设计可能影响不良事件报告和评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcomes for children and adults with advanced soft tissue sarcoma are poor with traditional therapy. We investigated whether the addition of pazopanib to preoperative chemoradiotherapy would improve pathological near complete response rate compared with chemoradiotherapy alone. METHODS: In this joint Children's Oncology Group and NRG Oncology multicentre, randomised, open-label, phase 2 trial, we enrolled eligible adults (aged ≥18 years) and children (aged between 2 and <18 years) from 57 hospitals in the USA and Canada with unresected, newly diagnosed trunk or extremity chemotherapy-sensitive soft tissue sarcoma, which were larger than 5 cm in diameter and of intermediate or high grade. Eligible patients had Lansky (if aged ≤16 years) or Karnofsky (if aged >16 years) performance status score of at least 70. Patients received ifosfamide (2·5 g/m2 per dose intravenously on days 1-3 with mesna) and doxorubicin (37·5 mg/m2 per dose intravenously on days 1-2) with 45 Gy preoperative radiotherapy, followed by surgical resection at week 13. Patients were randomly assigned (1:1) using a web-based system, in an unmasked manner, to receive oral pazopanib (if patients <18 years 350 mg/m2 once daily; if patients ≥18 years 600 mg once daily) or not (control group), with pazopanib not given immediately before or after surgery at week 13. The study projected 100 randomly assigned patients were needed to show an improvement in the number of participants with a 90% or higher pathological response at week 13 from 40% to 60%. Analysis was done per protocol. This study has completed accrual and is registered with ClinicalTrials.gov, NCT02180867. FINDINGS: Between July 7, 2014, and Oct 1, 2018, 81 eligible patients were enrolled and randomly assigned to the pazopanib group (n=42) or the control group (n=39). At the planned second interim analysis with 42 evaluable patients and a median follow-up of 0·8 years (IQR 0·3-1·6) in the pazopanib group and 1 year (0·3-1·6) in the control group, the number of patients with a 90% pathological response or higher was 14 (58%) of 24 patients in the pazopanib group and four (22%) of 18 patients in the control group, with a between-group difference in the number of 90% or higher pathological response of 36·1% (83·8% CI 16·5-55·8). On the basis of an interim analysis significance level of 0·081 (overall one-sided significance level of 0·20, power of 0·80, and O'Brien-Fleming-type cumulative error spending function), the 83·8% CI for response difference was between 16·5% and 55·8% and thus excluded 0. The improvement in pathological response rate with the addition of pazopanib crossed the predetermined boundary and enrolment was stopped. The most common grade 3-4 adverse events were leukopenia (16 [43%] of 37 patients), neutropenia (15 [41%]), and febrile neutropenia (15 [41%]) in the pazopanib group, and neutropenia (three [9%] of 35 patients) and febrile neutropenia (three [9%]) in the control group. 22 (59%) of 37 patients in the pazopanib group had a pazopanib-related serious adverse event. Paediatric and adult patients had a similar number of grade 3 and 4 toxicity. There were seven deaths (three in the pazopanib group and four in the control group), none of which were treatment related. INTERPRETATION: In this presumed first prospective trial of soft tissue sarcoma spanning nearly the entire age spectrum, adding pazopanib to neoadjuvant chemoradiotherapy improved the rate of pathological near complete response, suggesting that this is a highly active and feasible combination in children and adults with advanced soft tissue sarcoma. The comparison of survival outcomes requires longer follow-up. FUNDING: National Institutes of Health, St Baldrick's Foundation, Seattle Children's Foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Weiss AR, Chen YL, Scharschmidt TJ, et al. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2020. PMID: 32702309. doi:10.1016/S1470-2045(20)30325-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。